It still may not feel affordable to people with low incomes If you receive the low-income subsidy, also known as the Medicare Extra Help program, you cannot use that assistance for the drugs covered by the GLP-1 Bridge program
TRANSCEND-T2D-1 reported results on March 19, 2026 the first Phase 3 diabetes readout: These trials are expected to further broaden retatrutide's potential label across metabolic, musculoskeletal, and liver disease indications
This higher dose provides a treatment intensification option for patients with type 2 diabetes treated with semaglutide in need of additional glycaemic control
GLP-1 medications have also been associated with: Worsening of diabetic retinopathy Exacerbation of age-related macular degeneration Optic nerve complications, including NAION These risks dont mean you should stop taking your medication, but they do show why its important to have an eye exam before starting and regular follow-up exams while on treatment
Seeing the written pronunciations is helpful, so the written pronunciations are below and in the show notes on thepharmacistsvoice.com
Disproportionality analysis First, primary analysis was conducted to compare GLP-1RAs with other drugs in the FAERS database